FDA Reviewing Potential Anti-Arrhythmic Claims for... ( PALO ALTO Calif. Dec. 7 /- CV The...)

FDA Reviewing Potential Anti-Arrhythmic Claims for Ranexa(R)

Date:12/7/2007

PALO ALTO, Calif., Dec. 7 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) announced today that the U.S. Food and Drug Administration (FDA) has notified the Company that it will evaluate the approval of potential anti-arrhythmic claims for Ranexa(R) (ranolazine extended-release tablets) as part of its ongoing review of the Company's supplemental new drug application (sNDA).

This follows the FDA's acceptance of an sNDA seeking expansion to the approved product labeling for Ranexa to include a first line angina indication and a significant reduction in cautionary language as well as a separate NDA for a potential labeling change to add reduction of hemoglobin A1c (HbA1c) in coronary artery disease patients with diabetes. The two sNDAs are being reviewed by the FDA Division of Cardiovascular and Renal Products and the NDA is being reviewed by the FDA Division of Metabolism and Endocrinology Products.

The Prescription Drug User Fee Act (PDUFA) action date for the sNDAs and the NDA is July 27, 2008. The FDA has requested, and CV Therapeutics has paid three separate user fees to support the review of both sNDAs and the NDA.

"We anticipate receiving approval for first line angina use, which would significantly expand the patient population eligible to receive Ranexa, and we are very pleased that the FDA also is now evaluating separate potential anti- arrhythmic and HbA1c reduction claims for Ranexa on the same timeline," said Louis G. Lange, CV Therapeutics chairman and chief executive officer.

In September 2007, data published in Circulation and presented at the European Society of Cardiology Congress 2007 in Vienna, Austria showed that Ranexa reduced ventricular arrhythmias in pati
'/>"/>

0

GOOD

Page: 1 2 3
Related medicine news :

1. InstaCare Corp. Reviewing M&A Plans
2. Thomson Scientific Publishes its Third Quarter Issue of the Ones to Watch Reviewing the Most Promising Drugs in the Pharmaceutical Pipeline
3. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
4. UCLA study identifies designer estrogen as potential MS drug
5. Office-Based Medical Treatment and Internet Resources Are Potential Solution to Rising Painkiller Misuse Among Teens, Young Adults
6. Common abdominal pain may be due to a potentially treatable newly recognized inflammatory reaction
7. Potential new approach to treat cognitive impairments in schizophrenia
8. Nosespray vaccine using aloe vera has exciting potential, researcher says
9. Network approach identifies potential breast cancer susceptibility gene
10. Liver fibrosis will be treated by a potential target
11. Researchers study potential health benefits of natural chemicals in muscadine grape seeds

Post Your Comments:

FDA Reviewing Potential Anti-Arrhythmic Claims for...( PALO ALTO Calif. Dec. 7 /- CV The...),Health